Medication for treating calves in case of acute intestinal diseases

FIELD: medicine.

SUBSTANCE: invention relates to field of veterinary and is intended for treatment of calves in case of diarrhoea of infectious and alimentary-functional nature. Medication contains sodium chloride, hydrocarbonate, sodium chloride, glucose, iodine-bismuth complexonate (IBC) with the following component ratio, g/l of solution: sodium chloride - 3.5; sodium hydrocarbonate - 2.5; potassium chloride - 1.5; glucose - 20.0; IBC - 0.5.

EFFECT: application of the invention ensures increase of effectiveness and safety of treatment in case of acute intestinal diseases of calves.

2 dwg, 5 tbl, 2 ex

 



 

Same patents:

FIELD: medicine.

SUBSTANCE: invention is intended for prevention of post-infectious irritable bowel syndrome (PI-IBS). Peroral intake of autoprobiotic, representing individual lactic product, prepared on the basis of Enterococcus faecium strain, and containing 108 CFU in 1 ml of product. Inoculation of bacteria from patient's feces on selective nutritional medium is performed, with further culture growing in selective nutritional medium, identification and selection of colonies, typical for Enterococcus faecium, obtaining pure culture of Enterococcus faecium and specification of species and content of pathogenecity factors by method of polymerase chain reaction, selection of apatogenic clones of Enterococcus faecium, corresponding to standards of genetic safety and physiological functionality, which are used to prepare lactic starter culture. Autoprobiotic is introduced in dose not less than 100 ml/day, with course constituting not fewer than 10 days. Selected apathogenic clones of Enterococcus faecium are deposited in cryostorage at temperature not higher than -75C with storage term not longer than 1 year. Enterococcus-agar is used as selective nutritional medium.

EFFECT: method makes it possible to increase efficiency of prophylaxis of PI-IBS patients due to reduction of its development frequency.

3 cl, 1 tbl, 1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: claim describes prolonged release formulations containing an active ingredient presented by octreotide or its pharmaceutically acceptable salt and three various linear polymers of poly(lactide-co-glycolic acid) (PLGA). The first PLGA has the lactide:glycolic acid relation of 65:35; the second PLGA has the lactide:glycolic acid relation of 75:25; the third PLGA has the lactide:glycolic acid relation of 85:15. The octrotide composition containing three various linear polymers of PLGA is characterized by the plasma octreotide concentration of low variability over the period of time making more than three months.

EFFECT: composition is applicable for the prolonged supporting therapy of the patients suffering acromegalia and for treating diarrhoea and congestions associated with malignant carcinoids and tumours producing vasoactive intestinal peptides (VIPoma-like tumours).

18 cl, 4 tbl, 5 ex

FIELD: medicine.

SUBSTANCE: invention refers to veterinary medicine and can be used for treating and preventing gastrointestinal diseases accompanied by diarrhoeas in newborn calves Substance of the method consists in adding the oral administration of a therapeutic mixture of antibacterial, antitoxic and rehydration agents with the intramuscular injections of immunofan in a single dose of 1 ml 2-3 times every second day.

EFFECT: method provides increasing the therapeutic and preventive effectiveness in acute gastrointestinal diseases in newborn calves.

2 tbl, 2 ex

FIELD: chemistry.

SUBSTANCE: invention relates to novel macrocyclic alkylammonium derivatives of 6-methyluracil of formula (1). The compounds have anticholinesterase activity and can be used for pharmacological correction of synaptic defects which cause Alzheimer's disease, myasthenia gravis and other forms of pathological muscle weakness. The compounds can be used when treating glaucoma, intestinal atony, alcoholism, schizophrenia, manic-depressive psychosis, traumatic brain injury, sleep disorders, etc. In formula (1) X=NO2, Y=(CH2)4 (1a); X=CN, Y=(CH2)4 (1b); X=NO2, Y=C6H4 (1c); X=CN, Y=C6H4 (1d).

EFFECT: improved properties of compounds.

2 cl, 2 tbl, 9 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to gastroenterology, and can be used for providing the higher clinical effectiveness in the patients suffering dyspepsia syndrome combined with overweight. The method involves measuring an anxiety level (HARS) and a depression level (HDRS) according to Hamilton rating scales, assessing nutritional status by bioimpedancemetry, a degree of manifestation of sleep disorders, measuring glucose, testing glucose tolerance, immunoreactive insulin, cholesterol, high-density lipoprotein (HDLP), triglyceride in venous blood. If the patient is observed to suffer dyslipidemia and impaired glucose tolerance or variations of immunoreactive insulin, the preparation Dibikor is administered in a dose of 500 mg a day for three months. The patient suffering dyslipidemia and both of the disorders stated above requires administering Dibikor 1000 mg a day for three months. If the patient suffers an overweight with a body weight index falling within the range of 27 to 29.9 standard units and an active cell mass (ACM) percentage of 45 to 55 per cent as shown by bioimpedancemetry, the preparation Dietressa is administered in a dose of 1 tablet 3-4 times a day for three to six months. If the patient suffers an overweight with a body weight index falling within the range of 27 to 29.9 standard units and an active cell mass (ACM) percentage of 45 to 55 per cent as shown by bioimpedancemetry, the preparation Dietressa is administered in a dose of 2 tablet 3-4 times a day for three to six months. If the patient suffers mild and moderate sleep disorders and shows an emotive type of eating behaviour combined with mild affective disorders, the anti-depressant Valdoxane in a single dose of 25 mg a day for the night for two weeks. The course of the disease is followed by the anxiety and depression levels two weeks after the beginning of the therapy, with the positive progression of the diseases, the 25mg dose of Valdoxane remains unchanged to the end of the therapeutic course for three to six months. If no progression is exhibited, the dose is to be increased to 50 mg a day, and the therapy is continued from four to eight months. If the patient suffers severe sleep disorders and shows an emotive type of eating behaviour combined with moderate affective disorders, the anti-depressant Valdoxane in a single dose of 50 mg a day for the night for two to three months.

EFFECT: in each specific case, the method enables providing faster reduction of the clinical symptoms, including body fat weight reduction and active cell mass and water normalisation, normalising circadian rhythms of the vegetative balance, as well as prolonging the remission.

3 tbl, 2 ex

FIELD: veterinary medicine.

SUBSTANCE: agent or stimulation of metabolic processes, prevention and treatment of gastrointestinal diseases in calves in early postnatal period comprises succinic acid as the energy stimulant, beet molasses as carbohydrate component, methionine as the stimulant of the digestive system, iodinol as the anti-infective component, and water in the following ratio of components, based on 0.5 litre: succinic acid 5.0 g; beet molasses 150.0 ml; methionine 2.0 g; iodinol 30-50 ml; water - the rest.

EFFECT: improvement of agent efficiency.

5 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, particularly to paediatrics and neonatology, and can be used for treating small premature infants at the hospital stage of developmental care. A therapeutic complex comprises administering a probiotic preparation into the newborns. The preparation is presented with a liquid probiotic containing E.faecium L3 109 CFU in 1 ml. If the enteral nutrition volume of the newborn is 5 ml or more, this preparation is orally administered in a dose of 0.5 ml 3 times a day for 14 days.

EFFECT: method is effective in children with a very low body weight, promotes normalising the intestinal microflora and reducing a rate of manifestations of infectious complications.

2 ex, 3 dwg, 3 tbl

FIELD: chemistry.

SUBSTANCE: invention provides crystalline solid form of (S)-4-((2S,3S)-7-carbamoyl-1,1-diethyl-3-methoxy-1,2,3,4-tetrahydronaphthalin-2-ylamino)-2-cyclohexylmethyl-butyric acid or crystalline hydrochloride of (S)-4-((2S,3S)-7-carbamoyl-1,1-diethyl-3-methoxy-1,2,3,4-tetrahydronaphthalin-2-ylamino)-2-cyclohexylmethyl-butyric acid. Invention relates to pharmaceutical composition, possessing antagonistic activity with respect to mu-opioid receptor, which contains therapeutically effective quality of crystalline solid form.

EFFECT: invention provides methods of applying claimed crystalline solid forms in treatment of diseases associated with activity of mu-opioid receptors and methods of obtaining claimed crystalline solid forms.

27 cl, 9 dwg, 17 ex

FIELD: medicine.

SUBSTANCE: invention refers to veterinary science. A preparation for the prevention of diarrhoeas in newborn calves containing acid hydrolysate of animal blood, lactic, benzoic, succinic acids, additionally contains acetic acid, in the following ratio, wt %: acetic acid 0.4-0.5, lactic acid 0.05-0.06, benzoic acid 0.04-0.05, succinic acid 0.02-0.03, acid hydrolysate of animal blood - the rest.

EFFECT: invention provides a lower probability of diarrhoeas in the newborn calves and reducing a mortality rate.

3 tbl, 6 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine and may be used for relieving abdominal murmur. That is ensured by the oral administration of the bacteria Bifidobacterium animalis in dose 1109 CFU a day. The bacteria are administered every day, for at least 15 days.

EFFECT: method provides relieving abdominal murmur in a healthy individual that is ensured by the developed dose schedule and specific rate of administration of the above prebiotic.

10 cl, 1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to novel compounds of formula I, possessing ability of binding with delta-opioid receptors. In formula R1 is selected from the group, consisting of i) phenyl, optionally substituted with one-two substituents, independently selected from the group, consisting of C1-4alkyl, C1-4alcoxy, C1-4alkylthio, hydroxyl, di(C1-4alkyl), aminocarbonyl, chlorine and fluorine, in such a way that only one di(C1-4alkyl)aminocarbonyl is present; ii) naphthyl; iii) pyridinyl, optionally substituted with one substituent, selected from the group, consisting of C1-4alkyl, C1-4alcoxy, C1-4alkylthio, hydroxy, fluorine, chlorine and cyano; iv) pyrimidin-5-yl; v) furanyl; vi) thienyl; vii) 5-oxo-4,5-dihydro-[1,2,4]oxodiazol-3-yl; and viii) di(C1-2alkyl)aminocarbonyl; Y represents ethyl, vinyl or bond; or Y represents O, when R1 represents optionally substituted phenyl, where substituent represents C1-4alcoxy; R2 represents phenyl, optionally substituted with one-two substituents, independently selected from the group, consisting of C1-4alkyl, C1-4alcoxy, fluorine, chlorine and cyano, trifluoromethoxy and hydroxy; or R2 represents phenyl, substituted with one aminocarbonyl, di(C1-4alkyl)aminocarbonyl, C1-4alcoxycarbonyl or carboxysubstituent; R3 is selected from the group, consisting of i) 3-aminocyclohexyl; ii) 4-aminocyclohexyl; iii) piperidin-3-yl; iv) piperidin-4-yl; v) pyrrolodin-2-yl-methyl, in which pyrrolodin-2-yl is optionally substituted by 3-rd or 4-th position with one or two fluorine-substituents; vi) azetidin-3-yl; vii) 2-(N-methylamino)ethyl; viii) 3-hydroxy-2-aminopropyl; ix) piperidin-3-yl-methyl; x) 1-azabicyclo[2.2.2]octan-3-yl; and xi) 8-azabicyclo[3.2.1]octan-3-yl; or R3 together with Ra and nitrogen atom, which they both are bound to, form piperazinyl, optionally substituted with 4-C1-4alkyl; Ra represents hydrogen, 2-(N-methylamino)ethyl or C1-2alkyl, optionally substituted with azetidin-3-yl.

EFFECT: compounds can be used in treatment of pain in the range from medium to strong, caused by diseases or conditions, such as osteoarthritis, migraine, burn, fibromyalgia, cystitis, rhenite, neuropathic pain, idiopathic neuralgia, toothache, etc.

21 cl, 4 tbl, 26 ex

FIELD: veterinary medicine.

SUBSTANCE: agent for prevention of gastrointestinal diseases in calves with diarrhea syndrome comprises wt % silver nitrate 0.01-0.5, levamisole base 3.0-8.0, ascorbic acid 1.0-12.0 and water for injection - the rest.

EFFECT: antibacterial, immunomodulatory effect, anti-stress, antioxidant effect, and increase in effectiveness of prevention of gastrointestinal diseases in calves with diarrhea syndrome.

10 tbl, 6 ex

FIELD: veterinary medicine.

SUBSTANCE: method comprises giving to calves to drink the tincture of the combination herbal medicinal product - the grass of St. John's wort, meadowsweet, common yarrow, common nettle, rhizome of leather bergenia, root and rhizome of marsh cinquefoil, Scotch pine needles. At that the tincture fermented with microorganisms "EM Kurung" is used. The tincture is prepared by mixing 200 ml the tincture of the combination herbal medicinal product with 40 ml of the finished product "EM Kurung" and maintaining at the temperature of 18-20C during the day, followed by filtration. EM-preparation "Baikal EM 1" is given to dry cows for 30 days prior to calving as a single dose in a dose of 30 ml/head. Mixoferon, sedimin and nitamin are additionally prescribed to new-born calves according to the following schedule: from the second feeding the tincture of the combination herbal medicinal product is watered with colostrum, fermented with microorganisms of EM-preparation "EM Kurung" at a dose of 150 ml/head dualfold for 10 days. On the 1, 2 and 8 day of life, mixoferon is injected intramuscularly at a dose of 9 ml/head. On the 1 and 8 day of life - nitamin and sedimin at a dose of 4 ml/head.

EFFECT: use of the claimed method enables to increase the immunobiological reactivity, energy of growth, provides prevention of gastrointestinal diseases of new-born calves.

4 tbl, 3 ex

FIELD: packaging industry.

SUBSTANCE: present invention relates to packaging products sensitive to moisture. The probiotic product comprises lyophilised lactic acid bacteria mixed with anhydrous powder for solution for oral rehydration. At that the lyophilised lactic acid bacteria and the anhydrous powder for solution for oral rehydration are packaged in foil with a desiccant integrated into the foil. Also the method of long-term storage of viable lyophilised probiotic lactic acid bacteria is provided. The method comprises providing the anhydrous powder for solution for oral rehydration; mixing lyophilised lactic acid bacteria with anhydrous powder for solution for oral rehydration; packing the mixed lyophilised lactic acid bacteria and the anhydrous powder for solution for oral rehydration in the package comprising the chemical desiccant material inserted into a layer of foil; and sealing the package.

EFFECT: invention enables to extend the shelf life of the probiotic product.

13 cl, 1 dwg, 1 tbl, 4 ex

FIELD: chemistry.

SUBSTANCE: invention relates to novel derivatives of short-chain fatty acids, in particular derivatives of butyric acid, having physicochemical characteristics suitable for an easy oral administration, being devoid of the unpleasant organoleptic properties that characterise butyrate.

EFFECT: novel compounds have an easily weighable form, are stable to acids and alkalis and are capable of releasing the acid in the small and large intestines continuously over a long time.

7 cl, 5 dwg, 15 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: pharmaceutical composition for the reduction of a primary radiation response and an early transient incapacity containing ondansetron and gastrozepin in mass ratio 1-12:2-15; the composition is used as an injectable dosage form.

EFFECT: what is developed is the new composition.

3 cl, 3 tbl, 2 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry, particularly to using probiotics in the manufacture of a drug or a therapeutic nutritional composition for long-term prevention of diarrhea in infants. Using the probiotic Lactobacillus rhamnosus ATCC 53103 or Lactobacillus rhamnosus CGMCC 1.3724, and the probiotic Bifidobacterium longum ATCC BAA-999 in the manufacture of a drug or a therapeutic nutritional composition to be introduced into an infant for at least three months for the purpose of long-term prevention of diarrhoea, wherein the probiotic is introduced into a breastfeeding infant from a nursing mother.

EFFECT: using the above probiotic strains from the nursing mother is effective for the purpose of long-term prevention of diarrhoea in infants.

6 cl, 2 ex

FIELD: medicine.

SUBSTANCE: invention refers to veterinary science, and aims at treating viral diseases in animals. What is declared is a composition for treating viral diseases in animals, containing two subtypes of vertebrate recombinant interferon mixed in equal molar proportions.

EFFECT: use of the declared composition enables ensuring the substantial increase of the therapeutic effect of recombinant interferons and minimising the potential adverse effects associated with their use.

4 ex

FIELD: medicine.

SUBSTANCE: what is presented is the use of the strain Lactobacillus johnsonii in preparing a probiotic composition for prevention of postoperative abdominal and pelvic infections caused by pelvic liquid accumulation, anastomosis leakage, or caused by bacterial translocation.

EFFECT: colonic L Johnsonii Lai colonisation in the patients underwent colectomy for colorectal adenocarcinoma.

11 cl, 1 dwg, 1 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: invention relates to feeding of newborn babies delivered by Caesarian section. Claimed is change of composition which contains long-chain polyunsaturated fatty acid and, at least, one substance, selected from group, consisting of (a) nucleotide and (b) nucleotide precursor, selected from group consisting of nucleotides, purine bases, pyridine bases, ribose and deoxyribose for obtaining composition for introduction to newborn baby delivered by Caesarian section, for treatment and/or prevention of infection, diarrhea, intestine phlegmon, allergy, atopic eczema, asthma, allergic rhinitis and/or allergic conjunctivitis. Composition can also be used to improve intestinal maturation, reduction of intestinal permeability and/or for treatment of disorders associated with intestinal barrier, in newborn baby delivered by Caesarian section. Introduced to newborn baby composition is not human breast milk.

EFFECT: invention makes it possible to improve intestinal flora of newborn babies, delivered by Caesarian section.

12 cl, 5 tbl, 6 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to veterinary and can be applied in pig-breeding for the stimulation of exchange processes, growth activity, prevention of hypomicroelementosis and diarrhoeas of piglets. An energometabolic composition for the stimulation of exchange processes represents a water solution, which contains succinic acid, iodinol, beet molasses and sulphates of iron, copper, cobalt, zinc, with the following component content in 1000 ml of the solution: succinic acid - 10.0 g, iodinol - 250 ml, beet molasses - 300 ml, iron sulphate - 2 g, copper sulphate - 0.1 g, cobalt sulphate - 1 g, zinc sulphate - 0.3 g, water- the remaining part.

EFFECT: application of the invention will make it possible to improve exchange processes in piglets.

4 tbl

Up!